1. NNIS. Centers for Disease Control and Prevention (CDC). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
2. Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infection. Mayo Clin Proc. 2005;80:1201-1208.
3. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999-1005.
4. Eron LJ, Lipsky BA, Low DE. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52:i3-i17.
5. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2005;9:1415-1422.
6. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290:2976-2984.
7. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40:280-285.
8. Zelazny AM, Ferraro MJ, Glennen A, et al. Selection of strains for quality assessment of the disk inducer for detection of inducible clindamycin resistance in staphylococci: a CLSI collaborative study. J Clin Microbiol. 2005;43:2613-2615.
9. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445-1453.
10. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;41:
S269-S272.
11. Wilson MA. Skin and soft-tissue infections: impact of resistant gram-positive bacteria. Am J Surg. 2003;186: 35S-41S.
12. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250-278.
13. Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20:725-730.
14. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:
592-598.
15. NNIS. CDC. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2001, issued August 2001. Am J Infect Control. 2001;29:404-421.
16. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med. 1999;20:303-316.
17. CDC. Fact sheet: 12 steps to prevent antimicrobial resistance among surgical patients. Available at: http://www.cdc.gov/drugresistance/healthcare/surgery/12steps_surgery.htm. Accessed September 27, 2006.
18. Bratzler DW, Houck PM, for the Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706-1715.
19. Finkelstein R, Rabino G, Marshiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg. 2002; 123:326-332.
20. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24: 362-386.
21. Ostrander RV, Bottle MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87:980-985.
22. Kirby JT, Mutnik AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2002;43:303-309.
23. Lipsky BA, Pecoranro RE, Larson SA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Infect Dis Clin North Am. 1990;150:790-797.
24. Lipsky BA. Diabetic foot infections: progress in a pedestrian problem. Contemp Surg. 2001;57:S7-S19.
25. Reiber G, Lipsky B, Gibbons G. The burden of diabetic foot ulcers. Am J Surg. 1998;176:5-10.
26. Game F, Jeffcoate W. MRSA and osteomyelitis of the foot in diabetes. Diabet Med. 2004;21:16-19.
27. Hartemann-Heurtier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med. 2004;21:710-715.
28. Solomkin JS, Bjornson HS, Cainzos M, et al. A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am J Surg. 2004; 187:134-145.
29. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol. 2003;24:655-661.
30. Lucet JC, Chevret S, Durand-Zaleski I, et al. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med. 2003;163:181-188.
31. Lipsky VA, Berendt AR, Deerey, HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885-910.
32. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42:1303-1304.
33. Vancocin® HCl (sterile vancomycin hydrochloride, USP, intravenous) [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; 2001.
34. Zyvox® (linezolid injection, tablets, and oral suspension) [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn, a Pfizer Company; revised 2005.
35. Cubicin® (daptomycin for injection) [prescribing information]. Lexington, Mass: Cubist Pharmaceuticals; 2003.
36. Tygacil® (tigecycline for injection) [prescribing information]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2005.
37. Synercid® IV (quinupristin/dalfopristin for injection) [package insert]. Bristol, Tenn: Monarch Pharmaceuticals, Inc.; 2002.
38. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-1415.
39. Li Z, Wilke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. 2001;21:263-274.
40. Itani KM, Weigelt J, Li JZ, et al. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005;26:442-448.
41. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:60-2266.
42. Weigelt J, Haytham MA, Kaafarani MD, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004;188:760-766.
43. Cubist Press Release. January 16, 2002. Available at: http://www.cubist.com. Accessed May 17, 2006.
44. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR. 1997;46:813-815.
45. CDC. Staphylococcus aureus resistant to vancomycin — United States, 2002. MMWR. 2002;51:565-567.
46. CDC. Public Health dispatch: vancomycin-resistant Staphylococcus aureus — Pennsylvania, 2002. MMWR. 2002;51:902.
47. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38: 1700-1705.
48. Hussain FM, Boyle-Vavra S, Shete PB, et al. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
J Infect Dis. 2002;186:661-667.
49. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid skin and skin structure infection group.
J Antimicrob Chemother. 1999;44:263-273.
50. Stevens DL, Herr D, Lampiris H, et al. Linezolid vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34:1481-1490.
51. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000; 44:3408-3411.
52. Arbeit RD, Maki D, Tally F, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004:38;1673-1681.
53. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41:S341-S353.
54. Lipsky BA, Itani K, Norden C, et al. Treating foot infections in diabetic patients: A randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17-24.
55. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240-245.
56. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet. 2005;366:1695-1703. |
